Allergy Therapeutics plc (LON:AGY) insider Nicolas Wykeman purchased 150,000 shares of the stock in a transaction on Tuesday, September 27th. The shares were purchased at an average cost of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44).
Allergy Therapeutics plc (LON:AGY) traded up 9.58% during trading on Wednesday, hitting GBX 19.45. 936,578 shares of the stock traded hands. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 34.82. The stock’s market cap is GBX 108.83 million. The stock has a 50 day moving average price of GBX 18.69 and a 200-day moving average price of GBX 22.49.
Several equities analysts have weighed in on AGY shares. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 37 ($0.48) price target on shares of Allergy Therapeutics plc in a report on Tuesday. Panmure Gordon reissued a “buy” rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Friday, June 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.